Overview
Through innovative research and solid results, SomaGenics has made significant progress in its translation of discovery into products.
Therapeutic Pipeline
| Development Highlights |
| Hepatitis C |
- Lead identification complete with IC50 values to 5 picomolar in relevant models
- Identified chemical modification patterns that provide biostability and abrogate immune stimulation
- Achieved substantial knockdown of HCV target in mouse liver with formulated sshRNA
- IND Q3 2010
|
| Psoriasis |
- Genetic targets identified
- Animal models established
- Delivery proof-of-concept studies underway
|
| HIV |
- Early-stage discovery directed toward host targets in progress
|
| Gene-Specific Libraries |
- Proprietary production methods established
- Technology proof-of-concept complete; utilized in current HCV program and basis of HIV program
- Identifies sequences not predicted by algorithmic approaches
- Pooled probes for cost savings
|
Nucleic Acid Detection Technologies
SomaGenics has developed detection technologies that provide significant improvements in sensitivity and selectivity over those of competitors.
| Development Highlights |
| Lasso™ Probes |
- Optimization of structure and manufacture complete
- Technology proof-of-concept complete
- SNP detection capability
- Binding kinetics
- Increased signal-to-noise over current products
|
| miR-ID |
|
